Sfoglia per Autore
The achievement of durable complete cytogenetic remission in late chronic and accelerated phase patients with CML treated with Imatinib mesylate predicts for prolonged response at 6 years
2006 Piazza, R; Magistroni, V; Franceschino, A; Andreoni, F; Tornaghi, L; Colnaghi, F; Corneo, G; Pogliani, E; GAMBACORTI PASSERINI, C
Evidence for D276G and L364I Bcr-Abl mutations in Ph plus leukaemic cells obtained from patients resistant to Imatinib
2005 Piazza, R; Magistroni, V; Gasser, M; Andreoni, F; Galietta, A; Scapozza, L; GAMBACORTI PASSERINI, C
Imatinib dose increase up to 1200 mg daily can induce new durable complete cytogenetic remissions in relapsed Ph+ chronic myeloid leukemia patients
2005 Piazza, R; Magistroni, V; Andreoni, F; Franceschino, A; Tornaghi, L; Varella Garcia, M; Bungaro, S; Colnaghi, F; Corneo, G; Pogliani, E; GAMBACORTI PASSERINI, C
Bim promoter is highly methylated in malignant lymphoid cell lines, leading to downregulation of Bim expression and protection from apoptosis
2005 Piazza, R; Magistroni, V; Andreoni, F; Franceschino, A; GAMBACORTI PASSERINI, C
Response to ‘D276G mutation is associated with a poor prognosis in imatinib mesylate-resistant chronic myeloid leukemia patients’ by leguay et al
2005 Piazza, R; Magistroni, V; Franceschino, A; GAMBACORTI PASSERINI, C
Mechanisms of resistance to imatinib in chronic myeloid leukemia (CML) patients in chronic phase (CP) who achieved durable complete cytogenetic responses (CCR)
2003 Piazza, R; Magistroni, V; Tornaghi, L; Andreoni, F; Bungaro, S; Cazzaniga, G; Biondi, A; Pogliani, E; Varella Garcia, M; Corneo, G; GAMBACORTI PASSERINI, C
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile